As mRNA continues to enter and be adopted by the global healthcare community, the need to quickly validate and scale these ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Pfizer, Merck, AstraZeneca and Bristol Myers Squibb were among the many biopharmas showing off novel cancer modalities at ...

The deal focuses on ICT01, a monoclonal antibody being tested in acute myeloid leukemia. ImCheck is also developing assets in ...

The company cut back in areas while investing in internal and external opportunities to offset the loss of exclusivity on a ...

Seven in 10 U.S. hiring managers say their company usually considers employing overqualified applicants, according to a ...

While the threat of tariffs dies down for the pharma industry, President Donald Trump is reportedly weighing a new ...

Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN ...

Novo Nordisk’s leadership gets another shake-up as President Trump promises to significantly slash prices for its GLP-1 drugs ...

AI is changing the nature of leadership in biopharma. Here’s how executives can not only adapt, but lead the way.

Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework ...